Hydrogel–Nanolipid Formulations for the Complex Anti-Inflammatory and Antimicrobial Therapy of Periodontitis
<b>Objectives</b>: This study aimed to develop and evaluate nanostructured lipid carriers (NLCs) loaded with meloxicam (Melox) and a therapeutic antibacterial and anti-inflammatory liquid lipid, clove oil (CO) for periodontitis treatment, a complex inflammatory condition necessitating advanced drug delivery systems. The NLC-Melox formulation was integrated into three hydrogels, hypromellose (HPMC), zinc hyaluronate (ZnHA), and sodium hyaluronate (NaHA), to conduct a comparative analysis focusing on enhanced localized drug delivery, improved mucoadhesion, prolonged retention, and significant therapeutic outcomes. <b>Methods:</b> NLC-Melox was prepared by homogenization and characterized by dynamic light scattering (DLS). Subsequently, NLC-Melox-loaded gels were subjected to transmission electron microscopy (TEM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), Raman spectroscopy, and rheological analysis. In vitro drug release, anti-inflammatory activity (BSA denaturation assay), and antibacterial efficacy (MIC, MBC) were investigated to assess therapeutic potential. <b>Results:</b> DLS revealed a particle size of 183 nm with a polydispersity index of 0.26, indicating homogeneity. TEM confirmed consistent morphology and uniform nanoparticle distribution. DSC and XRD demonstrated the amorphous nature of Melox, enhancing solubility and stability. Spectroscopy confirmed no chemical interactions between components. Rheological studies identified ZnHA as the most mucoadhesive and structurally stable gel. In vitro release studies showed sustained drug release over 24 h. Melox and CO-loaded formulations demonstrated significant anti-inflammatory activity and notable antibacterial efficacy due to the antibacterial oil. <b>Conclusions:</b> The study highlighted the potential of NLC-based mucoadhesive hydrogels as an effective strategy for periodontitis treatment. The formulation offered improved drug solubility, therapeutic efficacy, mucoadhesivity, and prolonged delivery, making it a promising candidate for localized therapy.
Authors
- Katalin Burián (ORCID: https://orcid.org/0000-0003-1300-2374)
- Norbert Tóth (ORCID: https://orcid.org/0000-0002-9500-7322)
- Rabia Ashfaq
- Rita Ambrus (ORCID: https://orcid.org/0000-0001-5496-1710)
- Szilvia Berkó (ORCID: https://orcid.org/0000-0002-3842-8876)
- Tamás F. Polgár (ORCID: https://orcid.org/0000-0002-6287-1093)
- Mária Budai-Szűcs (ORCID: https://orcid.org/0000-0001-5187-5702)
- Anita Kovács (ORCID: https://orcid.org/0000-0001-5593-1329)
- Gábor Katona (ORCID: https://orcid.org/0000-0003-1564-4813)
- Mária Szécsényi (ORCID: https://orcid.org/0000-0002-0824-7062)
Institutions
- University of Szeged (HU)
- HUN-REN Szegedi Biológiai Kutatóközpont (HU)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-05-07
- DOI
- https://doi.org/10.3390/pharmaceutics17050620
- Citations
- 7
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 5.54
Funders
- Magyar Tudományos Akadémia